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Background: The study evaluates the osteogenic proper-
ties and biocompatibility of growth factor–rich demineral-
ized bone matrix (GDBM) by comparing with cancellous
mineralized bone matrix (CMBM) and anorganic bovine
bone matrix (ABBM).
Methods: Thirty-six Sprague-Dawley rats were used (n =
6/group/time point). To assess biocompatibility and osteo-
inductivity, the respective bone matrices were randomly
placed in subcutaneous pouches for 7 and 28 days and
evaluated by histology and osteopontin expression. Osteo-
conductivity was assessed by randomly implanting respec-
tive bone matrices in osteotomies on femurs for 14 and 28
days and evaluated by microcomputed tomography and
histology.
Results: Neither acute inflammation nor mineralized tissue
was noted in any of the subcutaneous specimens, whereas
expression of osteopontin was more prominent in the
GDBM group. Among the femoral specimens, the greatest
relative bone volume (bone volume [BV] divided by trabec-
ular volume [TV]) and trabecular thickness was noted in
the ABBM group at both time points, whereas less BV/TV
was noted in GDBM group at day 14. Residual matrix par-
ticles were noted in all examined groups at both time
points, without significant differences regarding defect fill
between groups. The GDBM group presented similar levels
of newly formed bone compartment and marrow space to
those of the ABBM group.
Conclusions: GDBM demonstrated acceptable biocom-
patibility and osteogenic potential comparable to ABBM in
vivo. Further investigations in a more clinically relevant model
are warranted. J Periodontol 2015;86:36-43.
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B
one grafts have been widely
used to aid in the reconstruction
of osseous dentoalveolar defects
as well as atrophic alveolar ridge aug-
mentation before implant placement.1,2
These range from autogenous bone
grafts (ABGs) and allografts to xeno-
grafts and alloplast or synthetic graft
materials.3 Ideally, the grafting material
must present adequate osteogenic, os-
teoinductive, or osteoconductive prop-
erties to achieve bone regeneration.4
ABG is considered the gold standard
grafting material because it possesses
the three abovementioned properties,
and the use of autografts diminishes the
risk of infectious disease transmission.5
Despite ABG being viewed as a reliable
treatment option, it always carries an
increased risk of donor-site morbidity
and limited availability. Freeze-dried bone
allograft (FDBA) appeared to be an
attractive alternative.6 However, FDBA
only served as a scaffold and did not
demonstrate a result comparable to
ABG.7
Osteoinductive factors (i.e., bone mor-
phogenetic proteins [BMPs]) insulated
by the mineral compartment could be
released only after demineralizing the
bone matrix (i.e., demineralized FDBA
[DFDBA]). Hence, DFDBA was con-
sidered to lead to a better osteogenic
potential relative to FDBA.8 However,
the osteoinductivity of DFDBAs could vary
according to the processing protocols,
carriers, and the source of allograft.9 In
* Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan.
† Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, MI.
‡ Faculty of Dentistry, National University of Singapore, Singapore.
§ Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University,
Taipei, Taiwan.
doi: 10.1902/jop.2014.140333
Volume 86 • Number 1
36
addition, the advent of efficient, safe processing and
sterilization techniques of ABG and FDBA have
spawned research into alternative substitutes, such
as xenografts with unlimited supply and no additional
donor site required for periodontal regenerative
procedures.10
Advances in molecular technology have dem-
onstrated that growth factors are a potential bi-
ologic agent to enhance craniofacial reconstruction,
periodontal regeneration, and implant site prepa-
ration.11 Growth factors are naturally occurring
polypeptides that target the appropriate cells to
carry out a specific biologic function. The most
commonly reviewed growth factors in the field of
dentoalveolar regeneration are platelet-derived growth
factor (PDGF) and BMPs.12,13 By promoting the
recruitment of mesenchymal stem cells and differ-
entiating to osteoprogenitor cells, BMPs have been
identified as the most potent osteoinductive ele-
ments and are now of considerable interest as
therapeutic agents for reconstructing dentoalveolar
defects as well as facilitating osseointegration of
dental implants.14 On the other hand, PDGF is a
chemotactic and mitogenic agent that has dem-
onstrated a beneficial effect in the regeneration of
the human periodontium.13,15 An in vitro study
demonstrated that recombinant human BMP-7
(rhBMP-7) combined with DFDBA stimulated the
early osteoblastic differentiation of human peri-
odontal ligament cells and suggested that DFDBA
could serve as a carrier for the growth factors.16
Being a controlled-release carrier, the combination
of DFDBA and growth factors provided good clin-
ical results in accelerating the healing of the peri-
odontal defects.17,18 Recently, a BMP-containing growth
factor–rich DFDBAi was introduced as a clinical
application for socket preservation and ridge aug-
mentation. However, little is known of its osteo-
inductivity and osteoconductivity relative to other
bone grafting materials.
This study aims to compare the properties of
growth factor–rich demineralized bone matrix
(GDBM) with other clinically available bone grafting
materials, including cancellous mineralized bone
matrix (CMBM) and anorganic bovine bone matrix
(ABBM), based on evidence from microcomputed




All animal procedures were performed under pro-
tocol no. 20130054 approved by the Institutional
Animal Care and Use Committee of the National
Taiwan University. Based on the results from the
authors’ previous study using the same species of
animals with a similar size of osteotomy,19 at least
20% difference was assumed in the relative bone
volume (bone volume [BV] divided by trabecular
volume [TV]) between the control and GDBM groups,
80% power, a = 0.05, and normal distribution and
equivalent variance of the samples. As a conse-
quence, a total of 36 (n = 6/group/time point) 8-
week-old male Sprague-Dawley rats were used in
this study.
The biocompatibility and osteoinductivity of the
graft materials were evaluated in the first part of the
study (Fig. 1A). Bilateral subcutaneous pouches were
created on the dorsum of the rats under general
anesthesia with intraperitoneal injection of 90 mg/kg
ketamine and 10 mg/kg xylazine described in a pre-
vious study.20 Each pouch was randomly filled with
300 mL of one of the following grafting materials: 1)
GDBM;¶ 2) CMBM;# and 3) ABBM.** The incision
was then closed by surgical staples. All animals were
given ampicillin (263 mg/L) in drinking water for 5
days and euthanized by 100% carbon dioxide at day
7 or 28.
The osteoconductivity of the graft materials was
evaluated in the second part of the study (Fig. 1B).
Under general anesthesia as described in the first
part, a 2.6-mm-diameter and 1.2-mm-depth osse-
ous defect was created bilaterally on the mid-
diaphysis of the femur by a customized drill with
copious normal saline irrigation. Each defect was
randomly filled with one of the graft materials
(GDBM, CMBM, or ABBM) or left empty (control).
All animals were given ampicillin for 5 days and
euthanized by 100% carbon dioxide at day 14 or 28.
Upon sacrifice, the tissue of the investigated areas
(subcutaneous pouches and femurs) was harvested
and stored in 10% formaldehyde at 4C for sub-
sequent examinations.
Micro-CT Assessments
An x-ray CT scanner†† was used to examine the
harvested femurs. The images were reconstructed
using the Shepp-Logan algorithm to achieve an
effective pixel size of 19 mm, and the threshold of
the image was determined by a local edge detection
algorithm,21 which showed the strongest correlation
to the histomorphometry among the current thresh-
olding algorithms from the authors’ previous study.22
The entire defect area was selected as the region of
interest (ROI), and the micro-CT parameters, in-
cluding BV/TV, trabecular thickness (Tb.Th), tra-
becular separation (Tb.Sp), and trabecular number
i Accell, Keystone Dental, Burlington, MA.
¶ Keystone Dental.
# Puros, Zimmer Dental, Carlsbad, CA.
** Bio-Oss, Geistlich Biomaterials, Wolhusen, Switzerland.
†† Shimadzu SMX-100CT x-ray CT scanner, Shimadzu Corp., Tokyo,
Japan.
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(Tb.N), were separately calculated for each ROI using
CT measurement software.‡‡
Histologic Examinations
After at least 3 days of formaldehyde fixation, all
the specimens were decalcified with 12.5% EDTA
for 3 weeks. The specimens were then cut through
the midline of the investigated area and embedded
in paraffin after dehydration. Three 5-mm sections
were made in the specimens from the subcutaneous
pouches. One was stained with hematoxylin and eosin,
and the others were stained for osteopontin (OPN),
a marker of osteogenesis. One 5-mm section was
made from femoral specimens and stained with
hematoxylin and eosin. All the images were acquired
using a digital image acquisition system.§§
Quantitative measurements on the specimens
from the subcutaneous pouches were performed
under ·400 magnification. The thickness of the fi-
brous capsule was measured in seven randomly
selected areas adjacent to the graft materials, and
the fractions of inflammatory cells were counted in
five randomly selected images adjacent to the graft
materials.
Histomorphometric measurements on the femoral
specimens were performed using digital measurement
softwareii under ·100 magnification (supplemen-
tary Fig. 1 in online Journal of Periodontology). The
defect fill was defined as the percentage of the well-
integrated osseous tissue, including new bone, marrow
space, and grafting materials, to the entire defect.
The percentage of each component of the osseous
tissue was also calculated. The distribution and
intensity of OPN deposition was evaluated in three
randomly selected images of each specimen under
·400 magnification. The quantitative measurements
were performed by a masked examiner: S-HY for
the histomorphometry and Y-HJ for the thickness
of fibrous capsule and inflammatory cells. The
inflammatory cells were identified based on the cell
morphology. All the histologic assessments were
supervised by a masked pathologist (Dr. Y-P Wang)
from the Pathology Department of the National
Taiwan University Hospital.
Statistical Analyses
One-way analysis of variance followed by Tukey
post hoc tests were used to compare the differences
of each parameter at each time point. The data are
presented as the mean – SD of measurements, with
a P value <0.05 considered statistically significant.
RESULTS
Histologic Assessments of the Subcutaneous
Specimens
Neither acute inflammation nor tissue necrosis was
noted in any of the subcutaneous specimens in-
vestigated. At day 7, the graft materials were em-
bedded in fibrous capsule with multinuclear giant
cells and inflammatory infiltration in all groups
(Figs. 2A through 2C). Histologic artifacts existed at
the interface of graft materials and surrounding
tissues in the ABBM and CMBM groups owing to the
demineralization process (Figs. 2B and 2C). OPN
was prominently expressed in the cells surrounding
the graft materials and lightly deposited in the in-
terstitial fibril matrix in the GDBM groups (Fig. 2A).
The OPN was similarly distributed but relatively lightly
deposited in the CMBM group (Fig. 2C), whereas
Figure 1.
Study design and animal model. Sprague-Dawley rats were used, and
six specimens were assessed in each graft material group at each time
point. A) Osteoinductivity and biocompatible properties were evaluated
by submerging the graft materials into the subcutaneous pouch. B)
Osteoconductivity was evaluated by filling the graft materials in the
surgically created osseous defect on the femur.
‡‡ CTAn, Bruker, Kontich, Belgium.
§§ AxioCam ICc 5, Carl Zeiss Microscopy, Munich, Germany.
ii AxioVision, Carl Zeiss Microscopy.
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OPN deposition was limited to the residual bone
matrix in the ABBM group (Fig. 2B). At day 28, the
cellularity as well as inflammatory infiltration was
apparently reduced in all groups (Figs. 2D through
2F), whereas multinuclear giant cell deposition on
the graft materials was still evident in the GDBM
group (Fig. 2D). OPN was still evidently deposited
in the cells and fibrils surrounding the graft mate-
rials in the GDBM and CMBM groups, and the
deposition was still limited to the residual bone
matrix in the ABBM group (Figs. 2D through 2F).
Therefore, none of the three tested materials showed
tissue mineralization at either time point.
The results from the quanti-
tative assessments demonstrated
that inflammatory infiltration was
minimal in all groups at day 7
and further decreased at day
28 (Fig. 2G). The fibrous capsule
surrounding the grafting mate-
rials was significantly thinner in
the CMBM group than the GDBM
and ABBM groups at day 7, and
no significant difference among
groups was noted at day 28 (Fig.
2H).
Micro-CT Assessments of the
Femoral Specimens
The border of the osseous defect
was distinguishable from the micro-
CT imaging in all the femoral
specimens (Fig. 3A). At day 14,
the defect was generally less radi-
opaque in the control and GDBM
groups than the CMBM group,
and the ABBM group showed the
highest radiopacity (Fig. 3A, up-
per panel). However, the obser-
vations might have just reflected
the differences in radiographic
density of the grating materials.
At day 28, the bone spongiosa
was apparently thicker compared
with that at day 14 in each group,
except the GDBM group (Fig.
3A, lower panel). The grafting
material was still distinguishable
from the new bone because of its
radiographic density in the ABBM
group, whereas the radiographic
density of the defect was similar
to the native bone in the CMBM
group.
Compared with the control,
BV/TV was significantly lower in
the GDBM group (P <0.05) but significantly higher
in the ABBM group (P <0.05) at day 14. At day 28,
only the ABBM group showed significantly higher
BV/TV relative to the control (P <0.01, Fig. 3B).
Significantly higher Tb.Th relative to the control was
only noted in the ABBM group at days 14 and 28
(P <0.01 and P <0.001, Fig. 3C), whereas signifi-
cantly lower Tb.N relative to the control was only
noted in the GDBM group at day 14 (P <0.01) (Fig.
3D). Therefore, compared with the control, Tb.Sp
was significantly higher in the GDBM group at day
14 (P <0.01) but significantly lower in the ABBM
group at day 28 (Fig. 3E). No significant difference
Figure 2.
A through F)Histologic assessments of the subcutaneous specimens at days 7 (D7) and 28 (D28).
H&E = hematoxylin and eosin; scale bar = 100 mm; asterisk = residual bone grafting materials;
arrowheads = OPN+ cells. A) Representative specimen from the GDBM group at day 7. B)
Representative specimen from the ABBM group at day 7. C) Representative specimen from the
CMBM group at day 7. D) Representative specimen from the GDBM group at day 28. E)
Representative specimen from the ABBM group at day 28. F) Representative specimen from the
CMBM group at day 28.G) Percentage of the inflammatory cells surrounding the grafting materials.
H) Averaged thickness of the fibrous capsule surrounding the grafting materials. *P <0.001
compared with the GDBM and ABBM groups.
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was noted in the CMBM group relative to the control
in any of the examined micro-CT parameters at
either time point.
Histologic Assessments of the Femoral
Specimens
At day 14, the defect was united and partially
occupied with newly formed osseous tissue, char-
acterized by thin trabeculae and enlarged osteocytic
lacunae, and lined with densely arranged osteo-
blastic cells in the control group (Fig. 4A). The
newly formed bone was well integrated to the res-
idues of the demineralized bone matrix, and the
formation of a marrow-like structure was noted in
the GDBM group (Fig. 4B). The histologic artifact
caused by the demineralization process was noted
in the ABBM and CMBM groups.
Most grafting materials were
bounded by thin lamellated bone
and marrow-like structure in the
ABBM group (Fig. 4C), whereas
the residual graft materials en-
capsulated by fibrous tissue were
evident in three of the six spec-
imens in the CMBM group (Fig.
4D).
At day 28, the defect was
nearly completely filled with newly
formed bone, and the trabeculae
were thicker with smaller lacunar
space relative to day 14 in the
control group (Fig. 4E). The re-
sidual graft materials were still
noted in all three other groups,
and most of the graft materials
were well integrated with the newly
formed bone (Figs. 4F through
4H). However, isolated graft ma-
terials without bone matrix de-
position were still noted in two of
the six specimens in the GDBM
and CMBM groups (Figs. 4F and
4H).
The defect fill was the highest
in the ABBM group at day 14,
and complete defect resolution
was noted in most specimens at
day 28, regardless of the treat-
ment (Fig. 5A). However, no
significant differences in defect
fill were found among groups at
the two time points. The marrow
space was slightly higher at day
14 in the control and CMBM
groups and apparently decreased
at day 28, whereas increasing
marrow space was noted in the GDBM group at day
28 (Fig. 5B). However, no significant differences in
percentage of marrow space area were found among
groups at either time point. The percentage of bone
component in the CMBM group was significantly
lower at day 14 than the control group. The dif-
ference was not statistically significant at day 28.
The percentage of bone component of the GDBM
group was statistically significantly lower than the
control group at day 28 (Fig. 5C).
DISCUSSION
In the first part of the study, minimal inflammation
and well-defined fibrous encapsulation were ob-
served in all three groups at both time points (Figs.
2G and 2H), indicating that all the examined graft
Figure 3.
Micro-CTassessments of the femoral specimens.A)Micro-CT imaging at days 14 (D14) and28 (D28).
Scale bar=1mm.B)BV/TV.C)Tb.Th.D)Tb.N.E)Tb.Sp.*P<0.05,†P<0.01,‡P<0.001comparedwith
the control group.
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materials presented acceptable biocompatibility. OPN,
a protein regulating the formation and remodeling
of mineralized tissue,23 was highly expressed in the
early stage in the GDBM group, implying that sig-
naling for osteogenesis was initialized. However, no
active mineralization was noted in any specimen
investigated, including the GDBM group. Although
growth factors have been known to enhance the
osteogenic process, and BMPs have been shown to
be fundamentally important regulators of osteogenesis
and osseous defect repair,24 the concentration of
the growth factor in the GDBM (<30 ng/g BMP-2
and <0.7 ng/g BMP-4) might not be sufficient to
trigger the process of mineralization, and at least
600 ng BMP-2 and 100 ng BMP-4 may be needed
in vivo.24,25 The fact that the bone grafting mate-
rials were not exactly confined in the subcutaneous
tissue and that the local concentration of growth
factors might be diluted and further reduces their
osteoinductive potential.
In the second part of the study, the micro-CT
assessments showed higher BV/TV and Tb.Th in the
ABBM group (Figs. 3B and 3C),
and lower Tb.N and higher Tb.Sp
was associated with the GDBM
group compared with the ABBM
and CMBM groups (Fig. 3). Al-
though the micro-CT imaging
provided three-dimensional struc-
tural configuration and showed
results comparable to the con-
ventional histology,26 all the ana-
lyses relied on only radiodensity
and might need special attention
when interpreting results in the
presence of bone grafting ma-
terials. For instance, ABBM and
CMBM are radiopaque materials
and are more likely to lead to
overestimation of the quantity of
newly formed bone, and the per-
formance of the GDBM group
might be underestimated since
it is more radiolucent. Thus, al-
though lower BV/TV and Tb.N
values were noted in the GDBM
group relative to the control group
at day 14 (Figs. 3B and 3D), it
could not be inferred that the
osteogenic property of the GDBM
Figure 4.
Histologic assessments of the femoral specimens under ·40 and ·400 original magnification at days
14 (D14) and 28 (D28). A) Specimen from the control group at day 14. B) Specimen from the
GDBM group at day 14.C) Specimen from the ABBM group at day 14.D) Specimen from the CMBM
group at day 14. E) Specimen from the control group at day 28. F) Specimen from the GDBM
group at day 28.G) Specimen from the ABBM group at day 28.H) Specimen from the CMBM group
at day 28. Scale bars in the ·400 images indicate 100 mm. The arrowheads in the ·40 images
indicate the borders of the defects, and the asterisks in the ·40 and ·400 images indicate the graft
materials. The dashed boxes in the ·40 images delineate the investigated areas in the ·400 images.
Figure 5.
Histomorphometry of the femoral specimens. A) Percentage of defect fill. B) Percentage of the marrow space of the osseous defect. C) Percentage of the
defect area solely occupied with the bony structure. *P <0.05 compared with the control group.
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group was inferior. In this regard, supplemental his-
tologic evidence is necessary. All examined groups
demonstrated similar levels of histologic defect fill
(Fig. 5A), and because of the presence of the re-
sidual grafting matrix, the real bone compartment in
all the grafted groups (i.e., GDBM, ABBM, and
CMBM) was lower relative to the control group (Fig.
5C). By subtracting residual grafting materials, all
grafting groups (i.e., GDBM, ABBM, and CMBM)
showed statistically comparable levels of marrow
space area as well as the area of bony component
(Figs. 5B and 5C), and the newly formed bone was
well integrated with grafting materials at day 28
(Fig. 4). The results support that ABBM and CMBM
have similar osteoconductive potential, which had
been reported in previous investigations,27,28 and
indicate that the osteoconductivity of GDBM was
equivalent with that of ABBM and CMBM. Although
it is generally accepted that ABBM could exhibit
osteogenic potential equivalent to DFDBA,29 in this
study, GDBM demonstrated equivalent osteocon-
ductivity relative to ABBM (Figs. 5A through 5C),
implying that the effect of growth factor was not
significant, and it could be associated with the fast
degradation or dilution of the growth factors. Spe-
cifically, rapid release of growth factors within the
first 2 days from the bone replacement grafts was
usually observed in several in vitro investiga-
tions.30,31 Furthermore, osteogenesis involves a
cascade of physiologic events timely mediated by
distinct growth factors. To maximize the osteogenic
capability of each growth factor, developing a bio-
compatible scaffold to control the release of growth
factors in appropriate stages is needed. For in-
stance, by using a bilayered microsphere composed
of poly-(D,L-lactide) and poly-(D,L-lactide-co-
glycolide) to encapsulate an early (e.g., PDGF) and
a late (e.g., simvastatin) bioactive molecule in the
respective compartment, the osteogenesis as well
as periodontal regeneration could be accelerated by
the controlled sequential release of bioactive mol-
ecules.32
Limitations of this study are: 1) traditional DFDBA
was not available for comparison; 2) critical-sized
defects were unable to be made in femurs due to
the small size of the femurs; and 3) false-positive
results are possible from statistical analyses. In
addition, these surgically created acute defects in
animals with high healing capability might not be
representative of human dentoalveolar defects.
CONCLUSIONS
Notwithstanding the limitations of the study, GDBM
demonstrated slightly greater osteoinductivity according
to the relatively prominent deposition of OPN, and
its osteoconductivity as well as biocompatibility was
equivalent to those of ABBM. From a clinical point
of view, the selection of the abovementioned ma-
terials should be based on other factors, such as
cost, ease of manipulation, and clinician preference.
Further investigations are warranted to confirm the
additive effect of growth factors in the DFDBA and
develop a suitable scaffold to control the release of
growth factors in a more clinically relevant model.
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